Group 1 - A new drug has been reported to slow cognitive decline in Alzheimer's patients by 36%, and by nearly 50% for a specific subgroup of patients [1] - The Biden administration's solar import duty policy is viewed as a significant barrier to the growth of clean energy [1] - The author has written extensively on various clean energy companies, including Canadian Solar and JinkoSolar, indicating a focus on the clean energy sector [1] Group 2 - The author has a beneficial long position in AVXL shares, reflecting confidence in the company's prospects [2] - The author previously held a long position in BIIB but no longer does, indicating a shift in investment strategy [2]

Core Insights - Blarcamesine, a drug candidate from Anavex, shows performance comparable to Aricept in treating Alzheimer's disease, indicating limited efficacy in addressing the disease's progression [1] - The underlying causes of Alzheimer's disease are linked to oxidation and nitration, with current treatments primarily targeting symptoms rather than the root causes [1] - Natural products like panax ginseng and essential oils may offer potential benefits by inhibiting oxidative stress and reversing some damage, suggesting alternative treatment avenues [1] - Anavex and Cyclo Therapeutics are highlighted as companies with promising drug candidates in the Alzheimer's space, making them recommended investment opportunities [1] Company Analysis - Anavex's long-term open label trial results are being reassessed to understand the mechanisms of action of its drug candidate, blarcamesine [1] - The company is positioned within a niche market focused on innovative treatments for Alzheimer's, which is characterized by a need for more effective solutions [1] - Cyclo Therapeutics is also mentioned as a company with potential in developing treatments that may stabilize Alzheimer's disease [1]

Core Viewpoint - Anavex Life Sciences Corp. is actively participating in two upcoming investor conferences, showcasing its focus on developing innovative treatments for various neurodegenerative and neurodevelopmental disorders, including Alzheimer's and Parkinson's diseases [1][2]. Company Overview - Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to developing novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders [2]. - The company's lead drug candidate, ANAVEX2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and is also being studied for Parkinson's disease dementia and Rett syndrome [2]. - ANAVEX2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its potential to halt or reverse Alzheimer's disease [2]. - The company is also developing ANAVEX3-71, which targets SIGMAR1 and M1 muscarinic receptors, showing promise in addressing cognitive deficits and other hallmarks of Alzheimer's disease in preclinical trials [2]. Upcoming Events - Anavex's President & CEO, Christopher U. Missling, PhD, will participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 2:30 pm ET [1]. - The company will also be present at the H.C. Wainwright 6th Annual Neuro Perspectives Conference on June 17, 2025, at 7:00 pm ET [1].

[PART I – FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) [Financial Statements](index=4&type=section&id=ITEM%201.%20FINANCIAL%20STATEMENTS) The company reported a net loss of **$23.3 million** for the six months ended March 31, 2025, with cash and cash equivalents at **$115.8 million** [Condensed Consolidated Interim Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Interim%20Balance%20Sheets) The balance sheet shows a decrease in cash and total assets, while total liabilities increased as of March 31, 2025 Balance Sheet Summary (in thousands) | Balance Sheet Items | March 31, 2025 (Unaudited) | September 30, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $115,771 | $132,187 | | Total Assets | $117,139 | $135,567 | | **Liabilities & Equity** | | | | Total Liabilities | $17,381 | $15,304 | | Total Stockholders' Equity | $99,758 | $120,263 | | Total Liabilities and Stockholders' Equity | $117,139 | $135,567 | - Cash and cash equivalents decreased by **$16.4 million** from September 30, 2024, to March 31, 2025, primarily due to funding of operations[15](index=15&type=chunk) - Total liabilities increased by approximately **$2.1 million**, mainly driven by a rise in accrued liabilities from **$4.8 million** to **$9.6 million**[15](index=15&type=chunk) [Condensed Consolidated Interim Statements of Operations and Comprehensive Loss](index=6&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) The statement of operations details increased research and development expenses, leading to a wider net loss for the period Statement of Operations Summary (in thousands, except per share data) | Metric | Three Months Ended Mar 31, 2025 | Three Months Ended Mar 31, 2024 | Six Months Ended Mar 31, 2025 | Six Months Ended Mar 31, 2024 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $9,892 | $9,729 | $20,338 | $18,413 | | General and administrative | $2,621 | $2,895 | $5,767 | $5,590 | | **Operating loss** | **($12,513)** | **($12,624)** | **($26,105)** | **($24,003)** | | **Net loss** | **($11,196)** | **($10,546)** | **($23,307)** | **($19,168)** | | **Net Loss per share (Basic & Diluted)** | **($0.13)** | **($0.13)** | **($0.27)** | **($0.23)** | - Research and development expenses increased to **$20.3 million** for the six months ended March 31, 2025, up from **$18.4 million** in the prior year period, reflecting increased clinical trial activities[16](index=16&type=chunk) [Condensed Consolidated Interim Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Cash%20Flows) Cash flow analysis reveals a significant decrease in cash from financing activities, contributing to an overall cash reduction Cash Flow Summary (in thousands) | Cash Flow Activity | Six months ended March 31, 2025 | Six months ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($17,976) | ($18,974) | | Net cash provided by financing activities | $1,560 | $7,336 | | **Decrease in cash and cash equivalents** | **($16,416)** | **($11,638)** | | **Cash and cash equivalents, end of period** | **$115,771** | **$139,386** | - Cash from financing activities significantly decreased to **$1.6 million** in the first six months of fiscal 2025, compared to **$7.3 million** in the same period of 2024. The 2025 proceeds were from stock option exercises, whereas 2024 included **$7.2 million** from the issuance of common shares[18](index=18&type=chunk) [Notes to the Condensed Consolidated Interim Financial Statements](index=10&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Interim%20Financial%20Statements) Key notes provide context on the company's biopharmaceutical focus, liquidity, and ongoing legal proceedings - The company is a clinical-stage biopharmaceutical firm focused on developing therapeutics for CNS diseases like Alzheimer's, Parkinson's, and Rett syndrome using a precision medicine approach[21](index=21&type=chunk)[22](index=22&type=chunk) - Management believes current working capital of **$99.8 million** is sufficient to meet requirements for more than 12 months, though future financing may be needed for ongoing R&D activities[28](index=28&type=chunk) - The company is subject to several shareholder class action and derivative lawsuits alleging violations of the Securities and Exchange Act of 1934 related to disclosures for ANAVEX2-73 clinical trials in Rett syndrome. The company believes the lawsuits are without merit and has not recorded any loss contingencies[62](index=62&type=chunk)[64](index=64&type=chunk)[65](index=65&type=chunk) - As of March 31, 2025, there was an unused amount of **$110.8 million** under the 2023 Purchase Agreement with Lincoln Park Capital, but a new registration statement is required to access these funds[53](index=53&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=19&type=section&id=ITEM%202.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS.) MD&A details the company's clinical-stage focus on CNS diseases, increased operating expenses, and a widened net loss, with sufficient capital for the next 12 months [Clinical Program Overview](index=22&type=section&id=Clinical%20Program%20Overview) This section outlines the progress of key clinical programs, including MAA submission for ANAVEX2-73 and trials for Rett syndrome and schizophrenia - **ANAVEX2-73 (blarcamesine):** The company submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in November 2024 for the treatment of Alzheimer's disease, which was accepted for scientific review in December 2024[101](index=101&type=chunk) - **Rett Syndrome Program:** The EXCELLENCE Phase 2/3 trial in pediatric patients was completed, showing improvement on the key co-primary endpoint RSBQ but not meeting the other co-primary endpoint, CGI-I. The open-label extension was completed in June 2024 with a high enrollment rate[115](index=115&type=chunk)[116](index=116&type=chunk)[119](index=119&type=chunk) - **ANAVEX3-71:** A Phase 2 trial in schizophrenia (ANAVEX3-71-SZ-001) commenced in March 2024. Enrollment for Part B was completed in May 2025, with top-line data expected in the second half of 2025[136](index=136&type=chunk)[138](index=138&type=chunk) - **Parkinson's Disease Dementia:** A Phase 2 proof-of-concept trial for ANAVEX2-73 was completed, demonstrating safety and statistically significant improvements in cognitive measures. The company plans further trials after regulatory consultation[104](index=104&type=chunk)[105](index=105&type=chunk)[108](index=108&type=chunk) [Financial Overview](index=34&type=section&id=Financial%20Overview) The financial overview highlights increased R&D expenses, a widened net loss, and a decrease in working capital Comparison of Operating Expenses (in thousands) | Expense Category | Three Months Ended Mar 31, 2025 | Three Months Ended Mar 31, 2024 | Six Months Ended Mar 31, 2025 | Six Months Ended Mar 31, 2024 | | :--- | :--- | :--- | :--- | :--- | | Research & Development | $9,900 | $9,700 | $20,300 | $18,400 | | General & Administrative | $2,600 | $2,900 | $5,800 | $5,600 | | **Total Operating Expenses** | **$12,500** | **$12,600** | **$26,100** | **$24,000** | - The increase in R&D expenses for the six-month period was primarily due to a **$3.7 million** increase in costs for the ANAVEX3-71 schizophrenia trial and a **$1.2 million** increase for ANAVEX2-73 manufacturing activities[173](index=173&type=chunk) Net Loss Summary | Period | Net Loss (in millions) | Loss Per Share | | :--- | :--- | :--- | | **Three Months Ended Mar 31, 2025** | $11.2 | $0.13 | | Three Months Ended Mar 31, 2024 | $10.5 | $0.13 | | **Six Months Ended Mar 31, 2025** | $23.3 | $0.27 | | Six Months Ended Mar 31, 2024 | $19.2 | $0.23 | - As of March 31, 2025, the company had working capital of **$99.8 million**, a decrease of **$20.5 million** from September 30, 2024, mainly due to cash used in operations[178](index=178&type=chunk) [Quantitative and Qualitative Disclosures About Market Risks](index=38&type=section&id=ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISKS.) This section is not required for smaller reporting companies, and therefore no information is provided - Disclosure is not required as the company qualifies as a smaller reporting company[195](index=195&type=chunk) [Controls and Procedures](index=38&type=section&id=ITEM%204.%20CONTROLS%20AND%20PROCEDURES) Management, including the principal executive officer and principal financial officer, evaluated the company's disclosure controls and procedures and concluded they were effective as of March 31, 2025. There were no material changes to the company's internal control over financial reporting during the quarter - Based on an evaluation as of the end of the reporting period, the company's principal executive officer and principal financial officer concluded that disclosure controls and procedures were effective[197](index=197&type=chunk) - No changes in internal control over financial reporting occurred during the quarter ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, these controls[198](index=198&type=chunk) [PART II – OTHER INFORMATION](index=39&type=section&id=PART%20II%20%E2%80%93%20OTHER%20INFORMATION) [Legal Proceedings](index=39&type=section&id=ITEM%201.%20LEGAL%20PROCEEDINGS) The company is subject to a shareholder class action lawsuit and two derivative lawsuits. These legal actions allege violations of the Securities Exchange Act of 1934 and breach of fiduciary duty, primarily related to disclosures about clinical trials for ANAVEX2-73 in Rett syndrome. The company has filed motions to dismiss and believes the claims are without merit - A shareholder class action complaint was filed on March 13, 2024, in the Southern District of New York, alleging violations of the Securities and Exchange Act related to disclosures for ANAVEX2-73 Rett syndrome clinical trials[200](index=200&type=chunk) - Two derivative lawsuits were filed on May 13, 2024, and February 14, 2025, against the company, an officer, and board members, based on similar allegations as the class action. These proceedings have been stayed pending a decision on the motion to dismiss in the class action lawsuit[202](index=202&type=chunk)[203](index=203&type=chunk) [Risk Factors](index=40&type=section&id=ITEM%201A.%20RISK%20FACTORS) The company highlights new and updated risks related to its business. Key risks include the lengthy, complex, and unpredictable nature of the marketing approval process with regulatory bodies like the EMA and FDA. A failure to obtain approval in one jurisdiction could negatively impact approvals elsewhere. Additionally, changes in U.S. and international trade policies, such as tariffs, could adversely affect business operations and costs - The marketing approval process for pharmaceutical products is highly regulated and unpredictable. A finding that the Phase 2b/3 trial for ANAVEX2-73 is insufficient could lead to the withdrawal of the MAA submitted to the EMA[205](index=205&type=chunk) - Obtaining regulatory approval in one jurisdiction does not guarantee approval in others, and failure in one may negatively affect processes elsewhere, potentially reducing the total market potential[207](index=207&type=chunk)[208](index=208&type=chunk) - Changes in U.S. and international trade policies, such as tariffs on pharmaceutical products and raw materials, could adversely impact the business, as demonstrated by increased costs already faced on imports from Canada[209](index=209&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=41&type=section&id=ITEM%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS) During the period covered by the report, the company did not sell any equity securities that were not registered under the Securities Act of 1933 and not previously reported on a Form 8-K - No unregistered sales of equity securities were made during the quarter that were not previously reported[210](index=210&type=chunk) [Other Information](index=41&type=section&id=ITEM%205.%20OTHER%20INFORMATION) No directors or Section 16 officers of the company reported the adoption, modification, or termination of a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the three-month period ended March 31, 2025 - No insider trading plans (Rule 10b5-1 or non-Rule 10b5-1) were adopted, modified, or terminated by directors or Section 16 officers during the quarter[213](index=213&type=chunk)

Financial Data and Key Metrics Changes - The cash position as of March 31 was $115.8 million with no debt [10] - Cash utilized in operating activities during the quarter was $5.9 million [10] - General and administrative expenses decreased to $2.6 million from $2.9 million year-over-year [11] - Research and development expenses increased slightly to $9.9 million from $9.7 million year-over-year [11] - The net loss for the quarter was reported at $11.2 million or $0.13 per share [11] Business Line Data and Key Metrics Changes - The company continues to focus on noninvasive targeted upstream precision compounds, particularly for Alzheimer's disease and schizophrenia [4] - Blacaramazine for Alzheimer's disease showed significant clinical benefits over three years of treatment [5] - Enrollment in the Phase II clinical study of ANAVEX 371 for schizophrenia was successfully completed with 71 participants [6][7] Market Data and Key Metrics Changes - The company is actively engaging with potential partners for the distribution of blacaramazine in Europe [27] - Discussions with CROs are ongoing to establish a sales force for potential drug launch [27] Company Strategy and Development Direction - The company aims to advance precision medicine compounds with a focus on scalable treatment alternatives for Alzheimer's and schizophrenia [13] - The strategy includes preparing for potential drug launches in various international markets, including Europe, Canada, and Australia [32][34] Management's Comments on Operating Environment and Future Outlook - Management expects feedback from the EMA regarding Alzheimer's treatment submission by the end of the year or early next quarter [15] - The focus remains on the safety and biomarker effects of the schizophrenia trial, addressing significant unmet needs in treatment [17][18] Other Important Information - The company has expanded its scientific advisory board with the appointment of experts in Alzheimer's disease [8] - The advantages of oral blacaramazine include timely access to treatment without logistical barriers, benefiting both patients and caregivers [46][49] Q&A Session Summary Question: Timeline for EMA feedback on Alzheimer's treatment - Management expects feedback by the end of the year or early next quarter, with no interim updates provided [15] Question: Key inflection points for 2025 - The focus is on the Phase II study in schizophrenia, particularly on safety and biomarker effects [17] Question: Details on the schizophrenia trial duration - The trial consists of two parts, with Part B lasting 28 days [23] Question: Pre-launch activities for blacaramazine in Europe - The company is in discussions with potential partners and CROs to ensure readiness for distribution [27] Question: Countries that might piggyback on European approval - Other regions include South America, Africa, the Middle East, and parts of Asia [31] Question: Parallel discussions with regulatory bodies - The company plans to initiate discussions with Canadian and Australian authorities in parallel with European feedback [34] Question: Revenue timeline post-approval - Revenue could potentially be realized in the March quarter, depending on logistical factors [41] Question: Drug manufacturing and launch inventory - The drug is manufactured by a major US manufacturer, and the company has a large launch inventory [42]

Financial Data and Key Metrics Changes - The company's cash position as of March 31 was $115.8 million with no debt [9] - Cash utilized in operating activities during the quarter was $5.9 million [9] - General and administrative expenses decreased to $2.6 million from $2.9 million year-over-year [10] - Research and development expenses increased slightly to $9.9 million from $9.7 million year-over-year [10] - The net loss for the quarter was reported at $11.2 million or $0.13 per share [10] Business Line Data and Key Metrics Changes - The company continues to focus on noninvasive targeted upstream precision compounds, particularly for Alzheimer's disease and schizophrenia [4] - Data from the open label extension of blacaramazine for Alzheimer's disease showed significant clinical benefits over three years [5] - Enrollment in the Phase II clinical study of ANAVEX 371 for schizophrenia was completed with 71 participants [6] Market Data and Key Metrics Changes - The company is receiving positive feedback from neurologists regarding the convenience of orally available treatment options for Alzheimer's disease [4] - The Phase II study for schizophrenia is expected to provide comprehensive clinical and biomarker data in the second half of the year [7] Company Strategy and Development Direction - The company aims to advance precision medicine compounds with a focus on scalable treatment alternatives for Alzheimer's and schizophrenia [12] - Discussions with potential partners for drug distribution in Europe are ongoing, with a focus on maximizing shareholder value [24][26] Management's Comments on Operating Environment and Future Outlook - Management expects to receive feedback from the EMA regarding Alzheimer's treatment submission by the end of the year or early next quarter [14] - The focus of the schizophrenia trial is on safety and biomarker effects, addressing the unmet needs in treating negative symptoms [15][16] Other Important Information - The company has expanded its scientific advisory board to enhance its research capabilities [7] - The drug blacaramazine is positioned to provide timely access to treatment without the logistical barriers associated with traditional therapies [43][46] Q&A Session Summary Question: Timeline for EMA feedback on Alzheimer's treatment - Management expects feedback from the EMA by the end of the year or early next quarter, with no interim updates provided [14] Question: Key inflection points for 2025 - The focus is on the Phase II study in schizophrenia, particularly on safety and biomarker effects [15] Question: Details on the schizophrenia trial duration - The trial consists of two parts, with Part B lasting 28 days [21] Question: Pre-launch activities for blacaramazine in Europe - The company is in discussions with potential partners and CROs to ensure quick access to the drug if approved [24] Question: Countries that might piggyback on European approval - The company plans to engage with regulatory bodies in various regions, including South America, Africa, and the Middle East [28] Question: Timeline for revenue post-approval - Revenue timelines vary by country, with some allowing immediate marketing post-approval [36] Question: Drug manufacturing and launch inventory - The drug is manufactured by a major US manufacturer, and the company has a large inventory ready for launch [38]

Core Viewpoint - Anavex Life Sciences Corp. is advancing its clinical-stage biopharmaceutical portfolio focused on innovative treatments for neurodegenerative diseases, particularly Alzheimer's disease and schizophrenia, with recent positive developments in clinical trials and financial results for Q2 fiscal 2025 [1][2]. Recent Highlights - The company successfully completed enrollment in its Phase 2 clinical study of ANAVEX®3-71 for schizophrenia, with a total of 71 participants [5]. - Anavex presented open-label-extension data for blarcamesine at the AD/PD™ 2025 conference, confirming its clinical benefits for early Alzheimer's patients [2]. - The appointment of Professor Dr. Audrey Gabelle to the Scientific Advisory Board enhances the company's expertise in Alzheimer's disease [5]. Financial Highlights - Cash and cash equivalents decreased to $115.8 million as of March 31, 2025, from $132.2 million at the end of fiscal 2024, indicating a runway of approximately 4 years at current utilization rates [5]. - General and administrative expenses for Q2 were $2.6 million, down from $2.9 million in the same quarter of fiscal 2024 [5]. - Research and development expenses increased slightly to $9.9 million compared to $9.7 million in the prior year [5]. - The net loss for Q2 was $11.2 million, or $0.13 per share, compared to a net loss of $10.5 million, or $0.13 per share, for the same quarter in fiscal 2024 [5][10].

Core Viewpoint - Anavex Life Sciences Corp. is set to release its financial results for the second fiscal quarter on May 13, 2025, and will host a conference call to discuss these results and the company's growth strategy [1][2]. Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, and Rett syndrome [1][4]. - The company's lead drug candidate, ANAVEX2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and is also being studied for Parkinson's disease dementia and Rett syndrome [4]. - ANAVEX2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its potential to halt or reverse Alzheimer's disease progression [4]. - Another promising drug candidate, ANAVEX3-71, targets SIGMAR1 and M1 muscarinic receptors and has shown beneficial effects in preclinical trials related to Alzheimer's disease [4]. Conference Call Details - The conference call will take place on May 13, 2025, at 8:30 am ET, and will include a question-and-answer session following management's remarks [2][3]. - Participants can access the call via a live webcast on Anavex's website or by dialing a specific number for U.S. participants [3].

Core Insights - Anavex Life Sciences Corp. has successfully completed enrollment for its Phase 2 clinical study of ANAVEX3-71, targeting schizophrenia, with a total of 71 participants [2][3][4] - The study consists of two parts: Part A with 16 participants focusing on multiple ascending doses, and Part B with 55 participants aimed at providing comprehensive clinical and biomarker data [3][4] - Top-line data from the study is expected to be reported in the second half of 2025 [5] Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia [2][7] - The lead drug candidate, ANAVEX2-73, has shown promise in multiple clinical trials for Alzheimer's disease and other CNS disorders [7][8] - ANAVEX3-71 is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator, which may address all symptom domains of schizophrenia without the side effects associated with standard antipsychotics [4][8] Industry Context - Schizophrenia affects nearly 24 million people globally, with significant unmet medical needs due to limitations of current treatments [6] - Approximately 34% of individuals with schizophrenia do not respond to existing therapies, and 50-60% experience only partial improvement or unacceptable side effects [6]

Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome [1][2] - The company's lead drug candidate, ANAVEX2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [2] Clinical Development - ANAVEX2-73 has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and studies in adult and pediatric patients with Rett syndrome [2] - The drug candidate is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its potential to halt or reverse Alzheimer's disease [2] Upcoming Events - Anavex will present at The Citizens Life Sciences Conference in New York on May 7-8, 2025, with a scheduled presentation by CEO Christopher U Missling at 3:30 PM (ET) on May 7 [1]